BNP Paribas Financial Markets Has $26.08 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

BNP Paribas Financial Markets cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 290,002 shares of the medical equipment provider’s stock after selling 58,655 shares during the quarter. BNP Paribas Financial Markets’ holdings in Zimmer Biomet were worth $26,077,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Key Financial Inc lifted its stake in Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at approximately $32,000. Grove Bank & Trust lifted its stake in Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 328 shares in the last quarter. Headlands Technologies LLC bought a new stake in Zimmer Biomet in the 2nd quarter valued at approximately $37,000. Finally, Basepoint Wealth LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at approximately $38,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $86.72 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $16.78 billion, a PE ratio of 22.52, a P/E/G ratio of 1.96 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The stock has a 50-day moving average price of $87.69 and a two-hundred day moving average price of $90.50.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period last year, the company earned $1.81 earnings per share. The firm’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 24.94%.

Insider Buying and Selling

In other news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.28% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus dropped their price objective on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. William Blair assumed coverage on Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating on the stock. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Wells Fargo & Company dropped their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. Finally, Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $102.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.